Pfizer Inc. (PFE) |
| 26.21 0.04 (0.15%) 06-12 16:02 |
| Open: | 26.29 |
| High: | 26.49 |
| Low: | 26.11 |
| Volume: | 38,606,334 |
| Market Cap: | 149,382(M) |
| PE Ratio: | 20.01 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 31.00 |
| Resistance 1: | 26.54 |
| Pivot price: | 25.86 |
| Support 1: | 25.71 |
| Support 2: | 25.19 |
| 52w High: | 28.75 |
| 52w Low: | 23.11 |
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
| EPS | 1.310 |
| Book Value | 15.810 |
| PEG Ratio | 13.77 |
| Gross Profit | 8.309 |
| Profit Margin (%) | 11.83 |
| Operating Margin (%) | 31.62 |
| Return on Assets (ttm) | 5.7 |
| Return on Equity (ttm) | 8.3 |
Fri, 12 Jun 2026
Pfizer Inc. $PFE Shares Bought by Xponance LLC - MarketBeat
Fri, 12 Jun 2026
Pfizer Inc. $PFE Stake Lowered by Swiss National Bank - MarketBeat
Fri, 12 Jun 2026
Pfizer Inc. $PFE Shares Sold by Logan Capital Management Inc. - MarketBeat
Fri, 12 Jun 2026
Pfizer Inc. $PFE Shares Purchased by IFM Investors Pty Ltd - MarketBeat
Fri, 12 Jun 2026
Alps Advisors Inc. Sells 57,526 Shares of Pfizer Inc. $PFE - MarketBeat
Thu, 11 Jun 2026
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |